✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

One missed PrEP dose is not the same as four. Four missed doses are not the same as a missed week. And the rules for restarting after any of those gaps depend not just on how long you missed, but on the type of exposure you’re protecting against — receptive anal sex behaves very differently from receptive vaginal sex in terms of how fast tenofovir reaches and leaves the target tissue. The single most common PrEP question that goes unanswered cleanly online is: “I missed my dose. Am I still protected, and what do I do now?”

This guide answers it directly. We walk through the 1-day, 2-day, 3-7-day, and >7-day missed PrEP dose scenarios, the restart protocols recommended by the CDC and WHO, the critical difference between TDF/FTC (Truvada generics like Tenvir-EM and Ricovir-EM) and TAF/FTC (Descovy), the additional caution required for cisgender women and transgender men, and when missing a dose should send you to PEP instead.

Missed PrEP Dose: 1-Day, 2-Day, and 1-Week Restart Protocols Explained

Reviewed by Morgan Ellis, Clinical Pharmacy Editor — MedsBase Medical Review Team. Last updated: 16 May 2026.

Quick Answer: What Should I Do If I Missed My PrEP Dose?

If you missed a daily PrEP dose by less than 24 hours, take it as soon as you remember and continue on schedule — protection is intact for receptive anal exposure and intact for receptive vaginal exposure if you’d already had 21+ days of consistent dosing before. If you missed 2 to 6 consecutive doses, take the next dose immediately, contact your prescriber, and consider that protection is reduced for vaginal exposure within that window. If you missed 7 or more consecutive doses, do not assume protection — restart with a 7-day load before relying on PrEP again.

Why Missed-Dose Math Matters: How PrEP Actually Builds Tissue Protection

Daily oral PrEP works by maintaining tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP) concentrations in HIV target cells above a protective threshold. The molecule reaches that threshold in different tissues at different rates. This is the single most important fact for understanding restart protocols, and it is rarely explained clearly.

Approximate time to reach protective tissue concentrations on daily TDF/FTC (Truvada / Tenvir-EM / Ricovir-EM):

• Rectal tissue: ~7 days of consistent daily dosing.
• Penile (insertive) tissue: ~7 days.
• Vaginal and cervical tissue: ~20 days.
• Bloodstream (peak): ~5 days.

Approximate tissue half-life after stopping:

• Rectal tissue: tenofovir-diphosphate persists for several days; protection is forgiving of 1–2 missed doses in MSM.
• Vaginal tissue: shorter persistence — missing doses costs protection faster.

This is why “I missed one pill” cannot be answered with a single universal rule. Two patients can ask the same question, receive different correct answers, and both be following CDC guidance — because the exposure type and prior adherence pattern fundamentally change the math.

The 1-Day Missed Dose: Almost Always Fine

You took yesterday’s PrEP at the usual time. Today you forgot until 6 PM, and your usual dose was 9 AM. That is a 9-hour delay.

The correct response: take today’s dose now, then tomorrow take the usual 9 AM dose as normal. Do not double-dose. Protection is intact for all exposure types provided you were already at steady state (i.e., you’d been on consistent PrEP for at least 7 days for MSM exposures or 21 days for vaginal exposures before this miss).

If the delay extends to “I remembered the next morning” — so roughly 24 hours late, taking yesterday’s dose at the same time as today’s scheduled dose — that is still within the forgiving window. Take both doses several hours apart, or take one and skip the original missed one to avoid GI side effects. Either approach maintains tissue protection because TFV-DP has not yet decayed below protective threshold in any major target tissue.

What does the published evidence say about this specific scenario? The iPrEx and Partners-PrEP analyses both showed that men taking 4+ doses per week (i.e., missing up to 3 doses per week) still achieved >95% efficacy in MSM. Missing one dose per week is well within that envelope. The 4-doses-per-week threshold is well documented in pharmacokinetic modelling — but note that the threshold is established for anal exposure, not for vaginal.

The 2-Day Missed Dose: Take the Next One, Watch the Pattern

Two days in a row missed. You realised on Wednesday morning that you forgot both Monday and Tuesday doses.

The correct response: take Wednesday’s dose immediately. Do not try to “catch up” by taking three pills at once — this risks GI side effects without restoring protection any faster. Continue daily dosing from Wednesday onwards.

For receptive anal exposure: protection is reduced but not eliminated. Tissue TFV-DP levels are likely still within the protective range if you were at steady state going into the missed window, but the margin is thinner. If a high-risk exposure occurred during the missed window, contact your prescriber within 24 hours — you may be a candidate for PEP rather than continued PrEP.

For receptive vaginal exposure: protection is meaningfully reduced. Cervical and vaginal tissue clears tenofovir faster than rectal tissue, and two missed doses within a week takes most cisgender women out of the consistent-protection range. If exposure occurred during the missed window, the conversation moves urgently to PEP.

If 2-day misses happen repeatedly (e.g., every couple of weeks), that is an adherence pattern issue. Talk to your prescriber about whether a switch to long-acting injectable cabotegravir, which removes the daily-dose problem entirely, might fit your situation better.

The 3-to-6-Day Missed Dose Gap: Restart Considerations

You forgot to refill, you travelled without your supply, or life happened — and four to six consecutive doses got missed.

The correct response shifts at this point. Take a dose as soon as you have access to PrEP again, then resume daily dosing. But do not assume protection is intact during the gap or for the first 24–72 hours after resuming. For MSM anal exposure, tissue TFV-DP levels will be below the protective threshold by day 5–6 of missed dosing. For vaginal exposure, they are below threshold within 2–3 days.

Practical implications for the days around the missed window:

• If a high-risk exposure occurred in the missed window OR within the first ~48 hours after resuming, escalate to PEP evaluation immediately.
• If no high-risk exposure occurred, resume daily dosing and allow 7 days (MSM anal) or 7–21 days (vaginal) before relying on PrEP protection for new exposures.
• Get tested for HIV at the next scheduled visit — sooner if any exposure occurred during the missed window. Acute HIV infection during a PrEP gap is a documented concern.

The 7+ Day Missed Dose Gap: Full Restart Protocol

If you have missed 7 or more consecutive days of PrEP, treat yourself as a restart — not a resume. Tissue tenofovir levels are below protective threshold in every relevant compartment, and the restart involves rebuilding to steady state before relying on protection.

For cisgender MSM and transgender women (TDF/FTC daily)

• Confirm HIV-negative status before restarting. A rapid HIV test or a fourth-generation HIV antigen/antibody test is the standard pre-restart check. PrEP started in someone with acute undiagnosed HIV infection carries a real risk of generating drug-resistant HIV.
• Take a dose immediately and resume daily dosing.
• Allow 7 days of consistent daily dosing before relying on PrEP for new receptive anal exposure.
• If a same-day exposure is anticipated, the 2-1-1 on-demand protocol (see next section) can provide bridge coverage — but only for cisMSM anal exposure.

For cisgender women and transgender men (TDF/FTC daily)

• Confirm HIV-negative status before restarting.
• Take a dose immediately and resume daily dosing.
• Allow 20 days of consistent daily dosing before relying on PrEP for new vaginal/cervical exposure.
• During the 20-day rebuild window, use condoms or other barrier methods. There is no shorter loading protocol established for vaginal exposure.

For Descovy (TAF/FTC) users

• Descovy is FDA-approved for PrEP only in cisgender MSM and transgender women — not for cisgender women or anyone at risk via receptive vaginal exposure (the DISCOVER trial did not enrol enough cisgender women to establish efficacy).
• If you are a cisMSM or transgender woman on Descovy and missed 7+ days, the restart logic mirrors TDF/FTC: confirm HIV-negative, resume daily, allow ~7 days before relying on protection for anal exposure.

The 2-1-1 On-Demand Protocol (and Why It Isn’t a “Restart”)

On-demand or event-driven PrEP (often called “2-1-1” PrEP) is a separate dosing strategy validated for cisgender MSM having receptive anal sex. It is not a restart protocol — it is an alternative dosing strategy that has its own missed-dose rules.

The 2-1-1 protocol:

• 2 pills of TDF/FTC taken 2–24 hours before anticipated anal exposure (the “double-dose” load).
• 1 pill 24 hours after the first dose.
• 1 pill 48 hours after the first dose.

The IPERGAY trial demonstrated 86% reduction in HIV acquisition for cisMSM using this regimen. The protocol is endorsed by the WHO and the European AIDS Clinical Society. It is not endorsed by the US CDC for primary use but is acknowledged as an option.

Critical limitations:

• Only validated for cisMSM having receptive anal sex.
• Not validated for cisgender women, transgender men, or receptive vaginal sex.
• Not recommended for users of hormonal therapy where drug interactions may complicate exposure.
• Requires the user to anticipate sex with at least 2 hours’ notice — not always realistic.

If you’ve been using 2-1-1 and missed a “1 pill at 24h” or “1 pill at 48h” follow-up dose after a double-dose load, take the missed pill as soon as you remember and continue the schedule. Skipping the 24h or 48h doses entirely after a single exposure substantially reduces protection.

Restart Protocol Summary Table

When to Switch From “Missed Dose” to PEP

If a high-risk exposure occurred during a missed-dose window — or any time PrEP protection is questionable — the conversation shifts from “restart PrEP” to “evaluate for PEP” (post-exposure prophylaxis).

PEP is a 28-day course of three antiretroviral drugs (typically tenofovir/emtricitabine plus a third agent like dolutegravir or raltegravir) started within 72 hours of a high-risk exposure. The earlier it is started, the more effective it is — every hour matters. PEP is not “extra PrEP”; it is a different regimen with different pharmacology and a much shorter window of opportunity.

Situations that should trigger immediate PEP evaluation rather than PrEP restart:

• You missed PrEP doses in the days leading up to a high-risk exposure (condomless receptive anal or vaginal sex with a partner of unknown or HIV-positive status, shared injection equipment, sexual assault).
• You had a high-risk exposure within 72 hours, regardless of PrEP timing.
• You are uncertain whether you are protected and the exposure was within 72 hours.

For lower-risk exposures (e.g., condomless insertive sex with a virally suppressed partner, oral sex), the standard restart protocols above are usually sufficient — discuss with your prescriber.

Special Considerations: Travel, Hormones, and Common Edge Cases

A few real-world situations deserve a moment of attention because they generate disproportionately many missed-dose questions.

Time-zone changes and travel

Sliding your dose time by a few hours each day across multiple time zones is usually fine — the absorption window is wide. A common-sense approach is to pick the new local time you want to dose at and shift gradually over 2–3 days. The bigger PrEP travel risk is not the time zone but the supply: customs delays, lost luggage, or running out before a return flight. Pack PrEP in carry-on, take double what you’ll need, and bring a clear-labelled supply rather than an unmarked pillbox.

Hormone therapy in transgender women

Studies have found small reductions in tenofovir drug concentrations among transgender women on feminising hormone therapy. The clinical implication is not “PrEP doesn’t work” but that adherence margin is tighter — daily dosing matters more, missed-dose forgiveness is reduced compared with cisMSM. Discuss with a clinician familiar with both gender-affirming care and PrEP.

Antibiotics and other co-medications

Most common antibiotics do not meaningfully interact with TDF/FTC or TAF/FTC. The exceptions worth flagging are nephrotoxic antibiotics (high-dose aminoglycosides, vancomycin) given concurrently with TDF, where additive renal stress is the concern rather than altered PrEP absorption. Routine antibiotic courses for STI treatment do not require pausing PrEP.

Stomach upset or vomiting after a dose

If you vomit within 1 hour of taking a PrEP dose, take another dose — the first one likely did not absorb. If you vomit more than 2 hours after dosing, absorption is mostly complete; do not redose. Between 1–2 hours, use judgement and check with your prescriber if uncertain.

Adherence Strategies That Reduce Missed Doses

If you’ve found yourself reading this guide more than twice, the practical answer is not better restart protocols. It is fewer missed doses in the first place. Established interventions with evidence behind them:

• Phone alarm + pill location consistency. Same time, same place every day. Most non-adherence is not about the alarm — it’s about the pill not being where the alarm goes off.
• Weekly pillbox. A visible 7-day organizer makes missed doses obvious within hours rather than days.
• Refill 14 days early. Travel, delayed shipping, lost prescriptions, supply issues — none of these cause missed doses if you’re 14 days ahead.
• Switch to long-acting injectable cabotegravir. Approved by the FDA in December 2021, cabotegravir LA (Apretude) is a once-every-2-months injection — no daily pill at all. Not currently available in all markets, but worth asking your prescriber if persistent daily-dose missed events are a pattern.
• Consider 2-1-1 if you’re cisMSM with infrequent or predictable exposure patterns. Some men find event-driven dosing easier than daily — but only if the criteria above apply to you.

For ongoing PrEP supply and product details, see our Tenvir-EM and Ricovir-EM product pages (both are WHO-GMP-certified TDF/FTC generics), the Truvada vs Descovy comparison for choosing between the two formulations, and the buying PrEP online guide for sourcing considerations.

Frequently Asked Questions

What happens if I miss one PrEP dose?

A single missed PrEP dose, taken less than 24 hours late, does not break protection for any exposure type provided you were already at steady state on daily dosing. Take the missed dose as soon as you remember, then continue your normal schedule the next day. Do not double-dose. This is the most forgiving scenario in PrEP adherence.

How many PrEP doses can I miss before protection drops?

For cisgender MSM having receptive anal sex, established evidence shows that 4 or more doses per week maintains protection above 95%. That means up to 3 missed doses per week is within the validated window. For cisgender women having receptive vaginal sex, the threshold is stricter — closer to 6 doses per week, with more rapid protection loss after any missed dose. The asymmetry comes from how fast tenofovir clears from different tissues.

Can I just take two pills the next day to catch up?

No. Doubling up does not restore tissue tenofovir levels any faster than single dosing and significantly increases the chance of nausea or other GI side effects. The correct approach is to take a single dose as soon as you remember, then continue daily dosing. If you’ve missed multiple days, take one dose now and contact your prescriber rather than attempting to make up the missed pills.

What’s the difference between missing PrEP doses for anal vs vaginal sex?

Tissue pharmacology. Tenofovir reaches protective concentrations in rectal tissue within 7 days of daily dosing and persists there for days after stopping. The same drug takes about 20 days to reach protective levels in vaginal and cervical tissue and clears from those tissues faster. As a result, the same missed-dose pattern produces different protection profiles depending on which exposure you’re protecting against.

Is missing one Descovy dose different from missing one Truvada dose?

Practically, for cisMSM anal exposure, no — both restart logics follow the same tissue-pharmacology pattern. Descovy (TAF/FTC) achieves slightly higher intracellular drug concentrations at lower plasma exposure, but the missed-dose forgiveness for receptive anal exposure is comparable. The important difference is indication: Descovy is not approved for cisgender women or for receptive vaginal exposure, so the “missed dose protocols for vaginal exposure” conversation does not apply to Descovy users.

Do I need to restart PrEP if I missed a week?

Yes — for any exposure type. Seven or more consecutive missed days takes tissue tenofovir below protective threshold in every relevant compartment. The restart requires confirming HIV-negative status first (PrEP started during undetected acute HIV infection can drive drug resistance), then resuming daily dosing, then waiting 7 days (anal exposure) or 20 days (vaginal exposure) before relying on protection again. Use barrier methods during the rebuild window.

What if I missed PrEP and had unprotected sex?

If the exposure was within 72 hours, contact a clinic immediately for PEP evaluation. PEP is a 28-day three-drug regimen started post-exposure, and it works best when started within 24 hours — every hour matters. Do not try to compensate with extra PrEP doses; PEP and PrEP are different regimens. After completing PEP, your prescriber will guide you back onto PrEP with appropriate testing.

Can I use 2-1-1 on-demand PrEP as a “restart” after missing daily doses?

Only if you meet the 2-1-1 criteria: cisgender man, receptive anal exposure, no hormonal therapy interactions. For everyone else, 2-1-1 is not a substitute for the daily restart protocol. Even for cisMSM, switching from daily to 2-1-1 requires planning around exposure timing (2 pills 2–24 hours before sex) that is not always realistic on short notice.

The Bottom Line

One missed PrEP dose is almost never a crisis. Two missed doses begin to matter, especially for vaginal exposure. Seven or more missed doses is a restart, not a resume — and the restart involves an HIV test first, then a deliberate rebuild period before relying on protection. The asymmetry between anal and vaginal tissue pharmacology drives most of the nuance in restart guidance; it is also the most-overlooked clinical fact in informal PrEP discussions online.

The single best protection against ever needing this guide is a 14-day-ahead refill habit. Most missed PrEP events trace back to running out of supply during a travel period or a delayed prescription rather than to forgetting a single pill on a normal day. If running out is the recurring pattern, fix the supply side. If forgetting daily is the recurring pattern, talk to your prescriber about long-acting injectable PrEP or about whether 2-1-1 fits your exposure profile.

For broader PrEP context, see our what is HIV PrEP and how does it work primer, the PrEP side effects guide for the early months, and the STI testing schedule that should run alongside any PrEP regimen. For ongoing supply, the Tenvir-EM and Ricovir-EM product pages cover the WHO-GMP-certified TDF/FTC options most PrEP users worldwide rely on.

Every order is covered by our Reshipment Assurance Policy: if your parcel does not arrive within 20 business days of dispatch (EMS or ITPS), we send a replacement at no extra cost.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.